Daiichi Sankyo Cuts Pay as Ranbaxy Reaches U.S. Settlement

Daiichi Sankyo Co. cut pay for executives and directors after slashing its profit forecast because of a $500 million provision to settle a legal dispute at its Ranbaxy Laboratories Ltd. unit in India.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.